Study reveals source of DNA mutations in melanoma

On July 30, 2021 Van Andel Institute reported that The mutations that give rise to melanoma result from a chemical conversion in DNA fueled by sunlight — not just a DNA copying error as previously believed, report a study by Van Andel Institute scientists published today in Science Advances (Press release, Van Andel Institute, JUL 30, 2021, View Source;utm_medium=rss&utm_campaign=pfeifer-melanoma-mutations [SID1234585461]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The findings upend long-held beliefs about the mechanisms underlying the disease, reinforce the importance of prevention efforts and offer a path forward for investigating the origins of other cancer types.

Gerd Pfeifer, Ph.D.

"Cancers result from DNA mutations that allow defective cells to survive and invade other tissues. However, in most cases, the source of these mutations is not clear, which complicates development of therapies and prevention methods," said Gerd Pfeifer, Ph.D., a VAI professor and the study’s corresponding author. "In melanoma, we’ve now shown that damage from sunlight primes the DNA by creating ‘premutations’ that then give way to full mutations during DNA replication."

Melanoma is a serious type of skin cancer that begins in pigment-producing skin cells. Although less common than other types of skin cancer, melanoma is more likely to spread and invade other tissues, which significantly reduces patient survival. Previous large-scale sequencing studies have shown that melanoma has the most DNA mutations of any cancer. Like other skin cancers, melanoma is linked to sun exposure, specifically a type of radiation called UVB. Exposure to UVB damages skin cells as well as the DNA within cells.

Most cancers are thought to begin when DNA damage directly causes a mutation that is then copied into subsequent generations of cells during normal cellular replication. In the case of melanoma, however, Pfeifer and his team found a different mechanism that produces disease-causing mutations — the introduction of a chemical base not normally found in DNA that makes it prone to mutation.

DNA comprises four chemical bases that exist in pairs— adenine (A) and thymine (T), and cytosine (C) and guanine (G). Different sequences of these pairs encode all of the instructions for life. In melanoma, the problem occurs when UVB radiation from the sun hits certain sequences of bases — CC, TT, TC and CT — causing them to chemically link together and become unstable. The resulting instability causes a chemical change to cytosine that transforms it into uracil, a chemical base found in the messenger molecule RNA but not in DNA. This change, called a "premutation," primes the DNA to mutate during normal cell replication, thereby causing alterations that underlie melanoma.

These mutations may not cause disease right away; instead, they may lay dormant for years. They also can accumulate as time goes on and a person’s lifetime exposure to sunlight increases, resulting in a tough-to-treat cancer that evades many therapeutic options.

"Safe sun practices are very important. In our study, 10–15 minutes of exposure to UVB light was equivalent to what a person would experience at high noon, and was sufficient to cause premutations," Pfeifer said. "While our cells have built-in safeguards to repair DNA damage, this process occasionally lets something slip by. Protecting the skin is generally the best bet when it comes to melanoma prevention."

The findings were made possible using a method developed by Pfeifer’s lab called Circle Damage Sequencing, which allows scientists to "break" DNA at each point where damage occurs. They then coax the DNA into circles, which are replicated thousands of times using a technology called PCR. Once they have enough DNA, they use next-generation sequencing to identify which DNA bases are present at the breaks. Going forward, Pfeifer and colleagues plan to use this powerful technique to investigate other types of DNA damage in different kinds of cancer.

Other authors include Seung-Gi Jin, Ph.D., Dean Pettinga, Jennifer Johnson and Peipei Li, Ph.D., of VAI.

Research reported in this publication was supported by Van Andel Institute and the National Cancer Institute of the National Institutes of Health under award no. R21CA228089 (Pfeifer). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

XBiotech Announces Payment of Dividend to Holders of Common Stock

On July 30, 2021 XBiotech Inc. (NASDAQ: XBIT) ("XBiotech") reported that it has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021 (Press release, XBiotech, JUL 30, 2021, View Source [SID1234585457]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the past 18 months, XBiotech’s balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human antibody drug candidates.

John Simard stated that "XBiotech was pleased to be able to reward its shareholders with a $2.47 per share dividend. Our ability to continue to provide opportunities for shareholders to monetize stock in XBiotech, reflects the strength of our fundamental approach to our industry. It begins with a visionary strategy to create a drug pipeline from natural human immunity—which offers an array of exceptional candidate therapeutics. Proprietary manufacturing technology developed at XBiotech has reduced our capital outlays needed for producing drug product, enabling us to build a drug development infrastructure debt-free. Integrating clinical operations has allowed us to conduct our own clinical trials, to test our breakthrough therapies, for a fraction of the cost of the standard industry approach, which involves the use of expensive clinical research contractors. Finally, from our manufacturing technology and clinical operations, we have generated contract revenue that has largely offset operating costs over the past two years. In short, we have stayed the course with our science and pushed the boundaries of industry practices to develop breakthrough therapies, reduce costs and create returns for our shareholders. We have never been more excited about our pipeline and opportunities than we are today."

About True Human Therapeutic Antibodies
XBiotech’s True Human antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

Posted Financial Results for 1Q/FY2021

On July 30, 2021 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, "the Company") reported the financial results for the first three months (April 1, 2021 – June 30, 2021) of the fiscal year 2021 (FY2021) ending March 31, 2022 (Press release, Astellas, JUL 30, 2021, View Source [SID1234585456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Qualitative information on consolidated financial results for the first three months of FY2021 (1) Business performance Consolidated financial results (core basis) in the first three months of FY2021 are shown in the table below. While revenue increased, core operating profit and core profit decreased.

Revenue-Sales of XTANDI for the treatment of prostate cancer and Strategic products XOSPATA for the treatment of acute myeloid leukemia, PADCEV for the treatment of urothelial cancer and Evrenzo for the treatment of renal anemia increased as expected.

-Moreover, factors for the increase in sales in the first three months of FY2021 included the growth of sales of Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder ("OAB"), and the sales of pharmacologic stress agent Lexiscan returning to pre-pandemic level which decreased mainly in the corresponding period of the previous fiscal year because of the impact of the spread of COVID-19.

-The sales growth of the products above offset the sales decrease mainly due to the termination of sales promotion activities for Celecox for the treatment of inflammation and pain, the transfer of manufacturing rights of Lipitor for the treatment of hypercholesterolemia, and the divestiture of Eligard for the treatment of prostate cancer.

As a result of the above, revenue in the first three months of FY2021 increased by 6.2% compared to those in the corresponding period of the previous fiscal year ("year-on-year") to ¥326.1 billion. Core operating profit/ Core profit-Gross profit increased by 6.7% year-on-year to ¥263.9 billion. The cost-to-revenue ratio fell by 0.4 percentage points year-on-year to 19.1%, mainly due to changes in product mix.-Selling, general and administrative expenses increased by 13.5% year-on-year to ¥137.1 billion.

The total amount increased due to the up-front investment to support CSP2021 initiatives (increase of Approx. ¥3.0 billion year-on-year), the increase of co-promotion fees associated with the growth of sales of XTANDI in the United States (increase of ¥3.0 billion year-on-year), the impact of the exchange rate (increase of ¥4.4 billion year-on-year), and moreover there was a one-off increase factor from the decrease of expenses for sales promotion activities and travel expenses due to the impact of the spread of COVID-19 in the corresponding period of the previous fiscal year (increase of Approx. ¥6.0 billion year-on-year). Excluding co-promotion fees associated with the growth of sales of XTANDI in the United States, selling, general and administrative expenses increased by 15.0% year-on-year to ¥102.6 billion.

-Research and development (R&D) expenses increased by 1.8% year-on-year to ¥58.3 billion. While there was a decrease in development expenses for fezolinetant, a selective neurokinin-3 receptor antagonist, for which patient enrollment in Phase III trials in the United States and Europe has been completed, the total amount increased mainly due to increases in development expenses for zolbetuximab, an anti-Claudin 18.2 monoclonal antibody and R&D investment for 3 Primary Focus, such as genetic regulation, cell therapy and immuno-oncology.-Amortisation of intangible assets increased by 1.8% year-on-year to ¥6.0 billion.

As a result of the above, core operating profit decreased by 0.9% year-on-year to ¥62.8 billion, and core profit decreased by 5.3% year-on-year to ¥49.2 billion. Impact of exchange rate on financial results The exchange rates for the yen in the first three months of FY2021 are shown in the table below. The resulting impacts were a ¥13.6 billion increase in revenue and a ¥6.1 billion increase in core operating profit compared with if the exchange rates of the first three months of FY2020 were applied.

Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs

On July 30, 2021 Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., "Minovia") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas" ) reported a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction (Press release, Astellas, JUL 30, 2021, View Source [SID1234585455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this strategic collaboration, Astellas and Minovia aim to accelerate the creation of allogeneic mitochondrial cell therapy programs. The two companies will jointly research cell therapy program candidates comprised of cells derived from Astellas’ proprietary genetically-engineered, induced pluripotent stem cells and augmented with Minovia’s proprietary MAT platform technology. The goal of these programs will be to treat diseases caused by mitochondrial dysfunction, through the transfer of healthy mitochondria to restore the patients’ tissues.

Minovia is a leading company in the field of mitochondrial cell therapy that utilizes mitochondrial transfer to deliver healthy mitochondria to a patient’s diseased cells. Minovia has a unique technology platform called Mitochondrial Augmentation Therapy (MAT), where the patient’s own cells are isolated, loaded with healthy mitochondria obtained from a healthy donor, and then re-infused back into the patient. Minovia is currently conducting research, development and clinical studies with MAT in mitochondrial diseases.

Astellas is engaged through its US subsidiary companies, Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells Inc., to advance allogeneic, off-the-shelf, differentiated cell therapy programs derived from pluripotent stem cells1. The new collaboration with Minovia extends Astellas’ capabilities in mitochondrial biology, and follow its recent acquisition of Mitobridge, Inc. and Nanna Therapeutics Limited2,3.

"We are excited and honored to collaborate with Astellas," stated Minovia’s Co-founder and Chief Executive Officer, Natalie Yivgi-Ohana, Ph.D. "We share with Astellas both their passion for mitochondrial science and their commitment to patients in need of new therapies. As Minovia continues the development of Mitochondrial Augmentation Therapy, we believe this partnership is critical to accelerate the development of off-the-shelf, allogeneic cell therapy programs for the many patients living with mitochondrial diseases caused by mitochondrial dysfunction."

Naoki Okamura, Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer, at Astellas said, "We, at Astellas, have positioned mitochondrial biology as one of the Primary Focuses of our research and development strategy to develop therapies for patients with unmet medical needs. One of the aspirations of this Primary Focus is to establish a mitochondrial cell therapy platform. Minovia is pioneering mitochondrial cell therapy and has unique technologies for enhancing delivery of healthy mitochondria to the patients’ cells. This strategic collaboration with Minovia will accelerate and expand our pipeline of treatment options for patients with diseases with underlying mitochodrial dysfunction."

Under the terms of the agreement, Minovia receives an upfront cash payment of $20M USD. Through the joint research program with Minovia, if Astellas develops and commercializes product candidates for diseases caused by mitochondrial dysfunction, Minovia is eligible to receive up to $420M USD per product in future development, regulatory and commercial milestone payments from Astellas.

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer

On July 30, 2021 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), reported that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021 (Press release, Lexicon Pharmaceuticals, JUL 30, 2021, View Source [SID1234585454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having previously built global medical organizations at three separate companies. Before joining Lexicon, Dr. Granowitz served as chief medical officer at Amarin Corporation plc, where he was a key leader on the company’s clinical development programs and held a number of other medical, safety and communications responsibilities. Prior to joining Amarin, Dr. Granowitz was senior vice president and head of global medical affairs, global human health at Merck & Co., Inc., where he developed and implemented an entirely new global medical affairs organization following Merck’s merger with Schering-Plough Corporation. Prior to the merger, he held a variety of medical and commercial management positions with Schering-Plough, including group vice president, head of global medical affairs.

"We are very pleased to have Dr. Granowitz join Lexicon as our chief medical officer," said Lonnel Coats, Lexicon’s president and chief executive officer. "He will be instrumental in building out our medical affairs organization and overseeing development of our pipeline. His experience as a physician, scientist and medical affairs leader with notable success in cardiovascular medicine makes him a particularly valuable addition to our management team as we prepare to file a new drug application for sotagliflozin as a therapy for people suffering from heart failure and living with type 2 diabetes."

"I am very excited to join the Lexicon team as we continue to advance sotagliflozin toward filing for regulatory approval," said Craig Granowitz, M.D., Ph.D. "The SOLOIST and SCORED studies clearly demonstrate the potential for sotagliflozin to improve the care of people living with type 2 diabetes and heart failure, particularly those with normal, or "preserved," left ventricular ejection fraction (≥ 50%). I look forward to the opportunity to build on the evolving science around sotagliflozin’s unique mechanism of action and the compelling scientific platform that forms the foundation for Lexicon’s drug discovery and development pipeline"

Dr. Granowitz earned his M.D. from the College of Physicians and Surgeons at Columbia University and his Ph.D. from the Graduate School of Arts and Sciences at Columbia University. He is a recognized expert in cardiovascular health and author of more than 30 peer-reviewed abstracts and manuscripts in respected journals and publications, including: The Journal of the American College of Cardiology, American Association of Clinical Endocrinologist, Academy of Managed Care Pharmacy, American Diabetes Association, American Heart Association, American Society for Preventative Cardiology, European Society of Cardiology, International Society for Pharmacoeconomics and Outcomes Research, National Kidney Foundation, the National Lipid Association and the New England Journal of Medicine.